Jingxin Pharmaceutical seeks HK IPO
Shenzhen-listed Jingxin Pharmaceutical has initiated a dual listing process aimed at a Hong Kong IPO. The company said proceeds will fund drug R&D and marketing as sales of its insomnia treatment didacinil expand following its inclusion in China’s national reimbursement list.